+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism



Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism



Cancer Research 52(8): 2148-2155



Biochemical and biological studies have been carried out with 2-desamino-2-methylaminopterin (dmAMT), which inhibits tumor cell growth in culture but is only a weak inhibitor of dihydrofolate reductase (DHFR). Since it was possible that the species responsible for growth inhibition are polyglutamylated metabolites, the di-, tri-, and tetraglutamates of dmAMT were synthesized and tested as inhibitors of purified recombinant human DHFR, murine L1210 leukemia thymidylate synthase (TS), chicken liver glycinamide ribonucleotide formyltransferase (GARFT), and murine L1210 leukemia aminoimmidazolecarboxamide ribonucleotide formyltransferase (AICARFT). The compounds with three and four .gamma.-glutamyl residues were found to bind two orders of magnitude better than dmAMT itself to DHFR, TS, and AICARFT, with 50% inhibitory concentration values in the 200 to 300 nM range against all three enzymes. In contrast, at a concentration of 10 .mu.M, dmAMT polyglutamates had no appreciable effect on GARFT activity. These findings support the hypothesis that dmAMT requires intracellular polyglutamylation for activity and indicate that replacement of the 2-amino group by 2-methyl is as acceptable a structural modification in antifolates targeted against DHFR as it is in antifolates targeted against TS. In growth assays against methotrexate (MTX)-sensitive H35 rat hepatoma cells and MTX-resistant H35 sublines with a transport defect, dmAMT was highly cross-resistant with MTX, but not with the TS inhibitors N10-propargyl-5,8-dideazafolic acid and N-{-5[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl)-N-methylamino]thenoyl}-L-glutamic acid, implicting DHFR rather than TS as the principal target for dmAMT polyglutamates in intact cells. On the other hand, an H35 subline resistant to 2'-deoxy-5-fluorouridine by virtue of increased TS activity was highly cross-resistant to N10-propargyl-5,8-dideazafolic acid and not cross-resistant to MTX, but showed partial cross-resistance to dmAMT. Both thymidine and hypoxanthine were required to protect H35 cells treated with concentrations of dmMT and MTX that inhibited growth by > 90% relative to unprotected controls. In contrast N10-propargyl-5,8-dideazafolic acid and N-{5-[N-(3,4-dihydro-2-mehtyl-4-oxoquinazolin-6-yl)-N-methylamino]thenoyl}-L-glutamic acid required only thymidine for protection. Like MTX, therefore, dmAMT appears to inhibit purine as well as pyrmidine de novo synthesis, and its effect on cell growth probably reflects the ability of dmAMT polyglutamates to not only block dihydrofolate reduction but also interfere with other steps of folate metabolism, either directly or indirectly via alteration of reduced folate pools. A similar protection pattern was obtained with mouse L1210 leukemia cells as with H35 cells, in that both thymidine and hypoxanthine were required for normal growth in the presence of dmAMT. Although folinic acid alone afforded full protection, 5-aminoimidazole-4-carboxamide could not be used instead of hypoxanthine, suggesting that de novo purine synthesis inhibition by dmAMT probably occurs at the level of AICARFT rather than GARFT. In antitumor assays against L1210 leukemia in mice, comparable lifespan increases were achieved with dmAMT and MTX, but more dmAMT than MTX had to be used to produce the same therapeutic effect. The results of this study suggest that dmAMT may be a promising lead for the development of other, more potent, 2-desamino analogues of classical 2,4-diamino antifolates.

(PDF emailed within 1 workday: $29.90)

Accession: 002036357

Download citation: RISBibTeXText

PMID: 1313737



Related references

Biochemical and biological studies on 2 desamino 2 methylaminopterin. Proceedings of the American Association for Cancer Research Annual Meeting 33: 552, 1992

Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase. Journal of Medicinal Chemistry 54(20): 7150-7164, 2012

Mechanism-based approaches to inhibition of the synthesis and degradation of folate and antifolate polyglutamates. Advances in Experimental Medicine and Biology 338: 639-643, 1993

Enzymatic synthesis of folate and antifolate polyglutamates with Escherichia coli folylpolyglutamate synthetase. Analytical Biochemistry 216(2): 345-351, 1994

Synthesis of folate and antifolate polyglutamates by fmoc chemistry and evaluation of methotrexate polyglutamate polylysine conjugates as inhibitors of h35 hepatoma cell growth. Proceedings of the American Association for Cancer Research Annual Meeting 30: 473, 1989

Synthesis and dihydrofolate reductase binding of 2 deamino 2 methylaminopterin polyglutamates. Proceedings of the American Association for Cancer Research Annual Meeting 32: 326, 1991

Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Molecular Pharmacology 45(4): 783-791, 1994

Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry. Journal of Medicinal Chemistry 52(9): 2940-2951, 2009

Structures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognition. Proceedings of the National Academy of Sciences of the United States of America 110(38): 15180-8, 2013

Folate pool interconversions and inhibition of biosynthetic processes after exposure of l1210 leukemia cells to antifolates experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamates in antifolate action in cells. Journal of Biological Chemistry 264(29): 17016-17023, 1989

Interaction of homofolate polyglutamates with folate enzymes from a human b cell lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 29: 285, 1988

Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum. Molecular Microbiology 51(5): 1425-1438, 2004

Studies on the regulation of one-carbon metabolism. The effects of folate concentration in the growth medium on the activity of three folate-dependent enzymes in Lactobacillus casei. Journal of Biological Chemistry 244(8): 1988-1993, 1969

Dietary monoglutamate and polyglutamate folate are associated with plasma folate concentrations in Dutch men and women aged 20-65 years. Journal of Nutrition 132(6): 1307-1312, 2002

Pharmacokinetic and toxicity studies with c 2 desamino c 2 substituted analogues of the antifolate n 10 propargyl 5 8 dideazafolic acid cb 3717. Proceedings of the American Association for Cancer Research Annual Meeting 29: 286, 1988